|
業務類別
|
Biotechnology |
|
業務概覽
|
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset,Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities. |
| 公司地址
| 100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, New Jersey, NJ, USA, 07932 |
| 電話號碼
| +1 646 305-6387 |
| 傳真號碼
| +1 646 882-4228 |
| 公司網頁
| https://www.beyondspringpharma.com |
| 員工數量
| 44 |
| Dr. June Lu, PhD |
Chief Scientific Officer |
美元 261.29K |
25/03/2026 |
| Dr. Lan Huang, PhD |
Chairman of the Board, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer |
美元 452.92K |
25/03/2026 |
|
|
| Mr. Patrick Fabbio |
Independent Director |
25/03/2026 |
| Dr. Lan Huang, PhD |
Chairman of the Board, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer |
25/03/2026 |
| Mr. Matthew Kirkby |
Independent Director |
25/03/2026 |
| Mr. Brendan Delaney |
Independent Director |
25/03/2026 |
| Dr. Sihai Xu, M.B.A. |
Director |
25/03/2026 |
| Dr. Jiangwen Majeti, M.B.A.,PhD |
Independent Director |
25/03/2026 |
|
|
|
|
